Dr. Daniel Bowles, MD
Medical Oncology (Medical Oncology Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Denver (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 66
Licensed in Colorado since 2007, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Colorado School of Medicine, Denver
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CO license 45842 (first issued 2007; active) -
Hematology & Oncology Physician
CO license 45842 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Uch-Memorial Health System Colorado Springs, CO
- Uchealth Highlands Ranch Hospital Highlands Ranch, CO
- Uchealth Broomfield Hospital Broomfield, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 181
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 127 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 34 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Aurora, CO | 25 |
| Gavreto (pralsetinib) | 24 |
| Tafinlar (dabrafenib mesylate) | 18 |
| Mekinist (trametinib dimethyl sulfoxide) | 18 |
| Bicalutamide | 16 |
| Ondansetron Hcl Other prescribers in Aurora, CO | 14 |
| Lenvima (lenvatinib mesylate) | 12 |
| Dexamethasone Other prescribers in Aurora, CO | 11 |
| Prochlorperazine Maleate Other prescribers in Aurora, CO | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $1,963 in total to this clinician.
| Eisai Inc. | $1,963 |
|---|
| Consulting Fee | $1,963 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Mar 5, 2025 | Consulting Fee Lenvima · Oncology | $1,963 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 7 companies. The companies reported $245,871 in research payments for these studies, mostly to the institutions running them.
- A phase 1 openlabel dose escalation and dose expansion study to evaluate the safety tolerability pharmacokinetics and anti tumor activity of PF07799933 ARRY440 as a single agent and in combination therapy in participa…
Pfizer Inc. - STARTRK 2 RXDX 101 02
Genentech, Inc. - A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05800015 - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176 - A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer
Exelixis Inc. - A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
Janssen Research & Development, LLC - Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
E.r. Squibb & Sons, L.l.c. · Completed · NCT01996865
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.